PALO ALTO, Calif.--(BUSINESS WIRE)--Anacor Pharmaceuticals (NASDAQ:ANAC) announced today the appointment of William J. Rieflin to its Board of Directors. Mr. Rieflin will also serve as chair of Anacor’s Audit Committee. Mr. Rieflin brings over 20 years of industry experience to Anacor. In October 2010, he was appointed Chief Executive Officer of NGM Biopharmaceuticals, a privately held biotechnology company. Previously, he was President of XenoPort, Inc. (NASDAQ:XNPT) and currently serves on XenoPort’s Board of Directors. Prior to that, he was Executive Vice President, Administration, Chief Financial Officer, General Counsel and Secretary for Tularik, Inc. (NASDAQ:TLRK), which was acquired by Amgen, Inc. in 2004. Previously, he was Vice President, Human Resources, General Counsel and Secretary for AMSCO International, Inc. (NYSE:ASZ). He was also an associate at Sidley & Austin in the corporate and securities department. He began his career as a sales representative for American Hospital Supply Corporation. Mr. Rieflin earned his B.S. from Cornell University, his M.B.A. from the University of Chicago Booth School of Business and his J.D. from Stanford Law School.
